




RealRate

PHARMACEUTICAL 2019

Iterum Therapeutics plc Rank 203 of 363





RealRate

PHARMACEUTICAL 2019

Iterum Therapeutics plc Rank 203 of 363



The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Iterum Therapeutics plc is the variable Research and Development, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 38% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	92,971
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,219
Liabilities, Non-Current	14,030
Other Assets	4,200
Other Compr. Net Income	0
Other Expenses	472
Other Liabilities	0
Other Net Income	-25
Other Revenues	869
Property and Equipment	700
Research and Development	68,647
Selling, General and Administrative Expense	8,781

Output Variable	Value in 1000 USD
Assets	97,871
Liabilities	26,249
Expenses	77,900
Revenues	869
Stockholders Equity	71,622
Net Income	-77,056
Comprehensive Net Income	-77,056
Economic Capital Ratio	74%